Accelerating lentiviral process optimization with multiparametric macro mass photometry

As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and analytical strategies must evolve together. In this joint webinar, Minaris Advanced Therapies and Refeyn will demonstrate how stable LVV production platforms and rapid single particle analytics can work in concert to accelerate development, improve process understanding, and reduce cost per batch.

In this webinar Qian Liu , Head of Viral Vector Process and Innovation at Minaris examines how stable packaging and producer cell line platforms, such as the XOFLX™ system, can support process development by reducing reliance on multi plasmid transfection and enabling greater flexibility in optimization strategies. These stable systems also unlock process improvements, such as intensification strategies, extended or continuous harvest, and the use of additives that may not be compatible with transfection-based approaches, supporting greater batch productivity and operational efficiency.

As process complexity increases, analytical tools that deliver timely and reliable measurements are essential. In this session, Hena Divanovic, Application Scientist at Refeyn will introduce macro mass photometry (MMP), a single particle analytical method capable of rapidly assessing lentiviral size, physical titre, and mass related contrast within minutes. MMP provides near real-time insights that enable improved process understanding and continuous refinement. Using XOFLX-derived LVV as a case example, the session will show how MMP data can deliver near real-time insight into vector quality and consistency and complementing functional assays such as transduction efficiency and strengthening process decision-making during development and scale-up.

Together, these case studies illustrate a more integrated model for LVV manufacturing, where stable production platforms and rapid analytics are aligned from early development through GMP manufacturing.

Learning Objectives:

• Overview of available support approaches for Cell and Gene Therapy (CGT) development, including how different tools and platforms can be integrated across the workflow.
• Understanding the role of stable packaging and producer cell line platforms in LVV manufacturing, and how they can influence scalability, consistency, and process design.
• How macro mass photometry can be applied to in process LVV samples to provide size and physical titre information that complements infectious titre measurements, supporting more efficient and informed process optimization.